$CNTA

Centessa Pharmaceuticals anticipates 2026 to be a "transformational" year as its lead orexin agonist, ORX750, approaches registrational studies for narcolepsy type 1, type 2, and idiopathic hypersomnia. The company is focused on dose selection, exploring once-daily and split-dosing regimens, with a Phase II update and trial initiation decisions expected in Q1. Centessa also plans to advance its next-generation asset, ORX142, into clinical trials this quarter, viewing orexin agonism as a broad neuroscience platform and moving towards a pre-commercial phase.